For research use only. Not for therapeutic Use.
Nefazodone is an antidepressant. Its chemical structure is unrelated to selective serotonin reuptake inhibitors, tricyclics, tetracyclics, or monoamine oxidase inhibitors (MAOI). Nefazodone has low affinity for the serotonin (200 nM), norepinephrine (360 nM), and dopamine (360 nM) transporters, and therefore acts as a weak serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).
| Catalog Number | I007700 |
| CAS Number | 83366-66-9 |
| Synonyms | Nefazodone, Dutonin, Nefadar, Serzone;2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one |
| Molecular Formula | C25H32ClN5O2 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one |
| InChI | InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3 |
| InChIKey | VRBKIVRKKCLPHA-UHFFFAOYSA-N |
| SMILES | CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl |
| Reference | </br>1:Endoplasmic Reticulum Stress Induction and ERK1/2 Activation Contribute to Nefazodone-Induced Toxicity in Hepatic Cells. Ren Z, Chen S, Zhang J, Doshi U, Li AP, Guo L.Toxicol Sci. 2016 Dec;154(2):368-380. Epub 2016 Sep 9. PMID: 27613715 </br>2:Involvement of mitochondrial dysfunction in nefazodone-induced hepatotoxicity. Silva AM, Barbosa IA, Seabra C, Beltrão N, Santos R, Vega-Naredo I, Oliveira PJ, Cunha-Oliveira T.Food Chem Toxicol. 2016 Aug;94:148-58. doi: 10.1016/j.fct.2016.06.001. Epub 2016 Jun 8. PMID: 27288927 </br>3:Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Lee S, Lee HA, Choi SW, Kim SJ, Kim KS.Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25. PMID: 26821276 </br>4:Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans. Nakada N, Kawamura A, Kamimura H, Sato K, Kazuki Y, Kakuni M, Ohbuchi M, Kato K, Tateno C, Oshimura M, Usui T.Biopharm Drug Dispos. 2016 Jan;37(1):3-14. doi: 10.1002/bdd.1990. PMID: 26352195 </br>5:A high-resolution accurate mass (HR/AM) approach to identification, profiling and characterization of in vitro nefazodone metabolites using a hybrid quadrupole Orbitrap (Q-Exactive). Perry SJ, Nász S, Saeed M.Rapid Commun Mass Spectrom. 2015 Sep 15;29(17):1545-1555. doi: 10.1002/rcm.7250. PMID: 28339156 </br>6:A novel assessment of nefazodone-induced hERG inhibition by electrophysiological and stereochemical method. Shin DS, Park MJ, Lee HA, Lee JY, Chung HC, Yoo DS, Chae CH, Park SJ, Kim KS, Bae MA.Toxicol Appl Pharmacol. 2014 Feb 1;274(3):361-71. doi: 10.1016/j.taap.2013.12.012. Epub 2013 Dec 26. PMID: 24374264 </br>7:A preliminary open trial of nefazodone added to mood stabilizers for bipolar depression. Goldberg JF.J Affect Disord. 2013 Jan 10;144(1-2):176-8. doi: 10.1016/j.jad.2012.04.037. Epub 2012 Aug 1. PMID: 22858262 </br>8:Effect of trazodone and nefazodone on hepatic injury induced by carbon tetrachloride. Abdel Salam OM, Sleem AA, Shafee N.Drug Discov Ther. 2010 Aug;4(4):285-97. PMID: 22491211 Free Article</br>9:Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Hagan JB, Erickson D, Singh RJ.Pain Med. 2010 Jul;11(7):1132-5. doi: 10.1111/j.1526-4637.2010.00852.x. Epub 2010 Apr 29. PMID: 20456080 </br>10:Utility of multivariate analysis in support of in vitro metabolite identification studies: retrospective analysis using the antidepressant drug nefazodone. Schneider RP, Zhang H, Mu L, Kalgutkar AS, Bonner R.Xenobiotica. 2010 Apr;40(4):262-74. doi: 10.3109/00498251003592691. PMID: 20178453 |
